Triquilar ED Tablets Blister Pack অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

triquilar ed tablets blister pack

bayer australia ltd - levonorgestrel, quantity: 75 microgram; ethinylestradiol, quantity: 40 microgram - tablet, sugar coated - excipient ingredients: povidone; lactose monohydrate; maize starch; montan wax; sucrose; magnesium stearate; macrogol 6000; calcium carbonate; purified talc - 1. oral contraception this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

ANGELIQ 1/2 tablet blister pack অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

angeliq 1/2 tablet blister pack

bayer australia ltd - estradiol hemihydrate, quantity: 1.033 mg (equivalent: estradiol, qty 1 mg); drospirenone, quantity: 2 mg - tablet, film coated - excipient ingredients: povidone; hypromellose; magnesium stearate; lactose monohydrate; purified talc; macrogol 6000; titanium dioxide; pregelatinised maize starch; maize starch; iron oxide red - hormone replacement therapy (hrt) for use in the short-term treatment in postmenopausal women with an intact uterus of the climacteric syndrome caused by deficient endogenous oestrogen production due to natural menopause, hypogonadism, castration or primary ovarian failure.

LOGYNON ED tablet blister pack অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

logynon ed tablet blister pack

bayer australia ltd - levonorgestrel, quantity: 0.05 mg; ethinylestradiol, quantity: 0.03 mg - tablet, sugar coated - excipient ingredients: purified talc; glycol montanate; lactose monohydrate; povidone; magnesium stearate; sucrose; calcium carbonate; maize starch; macrogol 6000 - oral contraception.

VERQUVO vericiguat 5 mg film-coated tablet blister pack অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

verquvo vericiguat 5 mg film-coated tablet blister pack

bayer australia ltd - vericiguat, quantity: 5 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; lactose monohydrate; microcrystalline cellulose; iron oxide red; sodium lauryl sulfate; purified talc; croscarmellose sodium; titanium dioxide - verquvo? is indicated in addition to standard of care therapy for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction less than 45[percent] who are stabilised after a recent heart failure decompensation event requiring admission and/or iv diuretic therapy (see section 5.1 pharmacodynamic properties ? clinical trials).

VERQUVO vericiguat 2.5 mg film-coated tablet blister pack অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

verquvo vericiguat 2.5 mg film-coated tablet blister pack

bayer australia ltd - vericiguat, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; lactose monohydrate; titanium dioxide; microcrystalline cellulose; purified talc; hypromellose; sodium lauryl sulfate - verquvo? is indicated in addition to standard of care therapy for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction less than 45[percent] who are stabilised after a recent heart failure decompensation event requiring admission and/or iv diuretic therapy (see section 5.1 pharmacodynamic properties ? clinical trials).

VERQUVO vericiguat 10 mg film-coated tablet blister pack অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

verquvo vericiguat 10 mg film-coated tablet blister pack

bayer australia ltd - vericiguat, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hypromellose; purified talc; titanium dioxide; croscarmellose sodium; sodium lauryl sulfate; iron oxide yellow; magnesium stearate - verquvo? is indicated in addition to standard of care therapy for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction less than 45[percent] who are stabilised after a recent heart failure decompensation event requiring admission and/or iv diuretic therapy (see section 5.1 pharmacodynamic properties ? clinical trials).